{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-005061","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.862118+00:00","generated_at":"2026-06-07T01:31:39.773493+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Revolution Medicines posts corporate presentation; no specific financial updates disclosed","bullets":["Corporate presentation dated January 9, 2024, titled 'On Target to Outsmart Cancer' posted on IR website.","Presentation outlines oncology pipeline strategy; no financial results, guidance, or material developments provided.","No new clinical data or major corporate events were disclosed in the filing or accompanying exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-005061","json":"https://secwatch.observer/filing/0001193125-24-005061.json","markdown":"https://secwatch.observer/filing/0001193125-24-005061.md","text":"https://secwatch.observer/filing/0001193125-24-005061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524005061/0001193125-24-005061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524005061/d106383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:31:39.773493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}